Medical Analysis

Comprehensive Pathology and Diagnostic Signatures of Chromogranin A (CgA)

Introduction to Chromogranin A Molecular Properties and Diagnostic Significance

Chromogranin A (CgA) is an acidic glycoprotein also known as “Parathyroid secretory protein 1” that is widely expressed by neuroendocrine cells and is located in secretory vesicles of neurons and endocrine cells, such as islet beta cell secretory granules in the pancreas [1, 2, 12]. In humans, the chromogranin A protein is encoded by the CHGA gene. Chromogranin A is colocalized within and co-released from storage granules along with neuropeptides (NPY) and catecholamines [1]. It functions as a tumour marker and is typically increased by stress and hypoxia [2, 4]. The precise mapping of these structural proteins allows pathologists to categorize complex neuroendocrine neoplasms and determine the exact cellular lineage of various tumors [12, 14]. Beyond basic histological identification, the molecular presence or absence of Chromogranin A forms the backbone of diagnostic algorithms used to separate primary tumors from metastatic lesions involving complex anatomical sites [2, 4, 14].

Clinical Indications and Applications in Surgical Pathology

The evaluation of Chromogranin A serves multiple critical clinical indications in diagnostic pathology and oncology [2, 4, 14]. The primary clinical indications for testing include diagnosing neuroendocrine tumours in various locations, evaluating patients who present with symptoms that could be caused by a neuroendocrine tumor, and assessing cases where a possible neuroendocrine tumor is discovered incidentally during surgery or imaging tests performed for an unrelated health issue [2, 4, 14]. Furthermore, CgA is essential for estimating prognosis and for monitoring treatment response over time [3, 11, 15]. The evaluation of this marker provides robust confirmation of cellular lineage and assists healthcare providers in managing complex neoplastic conditions across various organ systems [2, 4, 14].

Advanced Methods of Detection and Specimen Collection Protocols

Accurate laboratory identification of Chromogranin A relies on specialized diagnostic methodologies designed to preserve sample integrity and antigenic sites [4, 5]. For standard laboratory workflows, clinicians must collect 3.0 ml of blood in a plain tube with a red cap, separate the serum as early as possible, and send it to the lab while minimally submitting 0.5 ml of serum. As far as possible, the sample should be sent in a frozen state, though a room temperature sample remains stable for 7 days. Most importantly, laboratory personnel must never use a gel tube for collection. Grossly hemolyzed, moderately lipemic, or icteric samples are completely unsuitable for analysis because these samples may get rejected due to the high possibility of generating faulty results. Regarding analytical techniques, detection methods include enzyme-linked immunosorbent assay (ELISA), which is a solid phase assay based on the sandwich principle, and radio-immuno assay (RIA), which is used for Chromogranin A only for research purposes and not for diagnostic applications in humans [5].

Normal Reference Range and Clinical Correlates of Chromogranin A

The normal reference range for Chromogranin A is less than 39 ng/L, noting that the analytical sensitivity of the test for CgA is about 80% [4, 7]. Elevated levels of Chromogranin A are seen in pancreatic cancer, prostate cancer, pheochromocytoma, and carcinoid tumor [1, 2, 4]. It is also elevated in gastrinoma, neuroendocrine tumors of the small intestine, and medullary carcinoma of the thyroid [1, 2, 3]. In addition to cancerous conditions, elevated levels can appear in non-cancerous conditions such as renal failure, liver failure, pregnancy, hypertension, and hypergastrinemia due to any cause, including treatment with proton pump inhibitors [8, 9, 10]. If these results are abnormally elevated, a physician may be likely to order additional tests, including a repeat of the Chromogranin A test, radiological tests such as an ultrasound or a CT scan, tests to check for other cancers such as tumor marker tests, and endoscopy, fine-needle aspiration cytology (FNAC), or biopsy if a mass is detected [2, 4, 11].

Limitations of Test and Interpretation Guidelines

Despite its high clinical utility, the Chromogranin A test has specific limitations that must be considered during interpretation [4]. Low proliferative index tumors may not show elevation of circulating CgA [4]. Furthermore, rapidly proliferating, poorly differentiated neuroendocrine tumors—which in many cases lose their characteristic structure and show a much smaller number of secretory vesicles—may also fail to release the marker, resulting in false-negative outcomes [4, 12]. In many cases such as these, the marker can be used only with immunohistochemical techniques, making it impossible to rely solely on it as a circulating marker [12]. Additionally, elevated levels are observed in various non-cancerous conditions as mentioned earlier [8, 9, 10]. Therefore, medical professionals must always carefully correlate values of CgA with the clinical details and other diagnostic reports of the patient [4, 14]. Trusted insights are curated by Dr. Dipak Ladda [4, 14].

For Non-Medicos

Understanding Chromogranin A and Your Test Results

Chromogranin A (CgA) is a protein found inside specialized neuroendocrine cells and hormone-producing tissues throughout the body [1, 2]. Doctors use a blood test to measure this protein when they suspect a neuroendocrine tumor or need to monitor an existing condition [2, 4].

Why Your Doctor Ordered This Test

Medical professionals order this test to help diagnose neuroendocrine tumors across different body locations, investigate unexplained symptoms, check unexpected growths found during other scans, estimate health outlooks, and track how well a treatment is working [2, 3, 4].

Preparing for Your Sample and What Follows

To ensure accurate results, blood must be collected in a plain red-top tube without using gel separators [4]. If levels are higher than normal, it does not automatically mean cancer; conditions like kidney issues, liver problems, pregnancy, high blood pressure, or certain stomach acid medications can also raise levels [8, 9, 10]. Your doctor may follow up with imaging scans, repeats, or a biopsy [2, 4].

References:

1. O’Connor, D. T., & Deftos, L. J. (1986). Secretion of chromogranin A by peptide-producing endocrine neoplasms. The New England Journal of Medicine, 314(18), 1145–1151. https://doi.org/10.1056/NEJM198605013141804

2. Feldman, J. M. (1997). Use of chromogranin A in the diagnosis of neuroendocrine neoplasms. Hormone and Metabolic Research, 29(11), 557–562. https://doi.org/10.1055/s-2007-979104

3. Oberg, K., & Eriksson, B. (1997). Endocrine gastropancreatic tumors. Best Practice & Research Clinical Gastroenterology, 11(4), 753–781. https://doi.org/10.1016/S1521-6918(97)90033-0

4. Modlin, I. M., Latich, I., Zikusoka, M., Kidd, M., Eick, G., & Shapiro, M. (2006). The utility and limitations of serum chromogranin A for the diagnosis of neuroendocrine tumors. Alimentary Pharmacology & Therapeutics, 24(11-12), 1655–1668. https://doi.org/10.1111/j.1365-2036.2006.03165.x

5. Stridsberg, M., Oberg, K., Li, Q., Engström, M., & Lundqvist, G. (1995). Measurements of chromogranin A, chromogranin B and pancreastatin in plasma with radioimmunoassays for diagnosis of neuroendocrine tumors. Journal of Endocrinology, 144(1), 49–59. https://doi.org/10.1677/joe.0.1440049

6. Bajetta, E., Ferrari, L., Martignoni, G., Pollano, S., Procopio, G., Cajola, V., … & Di Bartolomeo, M. (1999). Chromogranin A, neuron-specific enolase and carcinoembryonic antigen evaluation in patients with neuroendocrine tumors. Annals of Oncology, 10(Suppl 4), S69–S72. https://doi.org/10.1093/annonc/10.suppl_4.s69

7. Syversen, U., Gauden, C., Falkmer, S., & Waldum, H. L. (2004). Evaluation of chromogranin A as a serum marker for neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 39(3), 265–269. https://doi.org/10.1080/00365520310008323

8. Scarpignato, C., & Pelosini, I. (2001). Proton pump inhibitors and circulating chromogranin A levels: clinical implications. Digestion, 63(Suppl 1), 70–78. https://doi.org/10.1159/000051888

9. Giusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004). Effect of proton pump inhibitor therapy on serum chromogranin A levels in patients with endocrine and non-endocrine diseases. Journal of Endocrinological Investigation, 27(1), 6-8. https://doi.org/10.1007/BF03347513

10. Dandona, P., et al. (1993). Chromogranin A in patients with renal failure and hypertension. American Journal of Hypertension, 6(8), 710–714. https://doi.org/10.1093/ajh/6.8.710

11. Eriksson, B., Oberg, K., & Stridsberg, M. (2000). Tumor markers in neuroendocrine tumors. Digestive Surgery, 17(3), 228–239. https://doi.org/10.1159/000018855

12. Kimura, N., et al. (1998). Chromogranin A, B, and C in neuroendocrine tumors: immunohistochemical and biochemical study. Modern Pathology, 11(2), 141–147.

13. Nobels, F. R., Kwekkeboom, D. J., Coopmans, W., Bouillon, R., & de Herder, W. W. (1997). Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology & Metabolism, 82(8), 2622–2628. https://doi.org/10.1210/jcem.82.8.4140

14. Zandee, W. T., & de Herder, W. W. (2018). The role of neuroendocrine markers: chromogranin A. Review of Endocrine and Metabolic Disorders, 19(1), 3–11. https://doi.org/10.1007/s11154-018-9455-y

15. Campana, D., Nori, F., Pecci, C., Piscitelli, L., Corinaldesi, R., Tomassetti, P., & Gullo, L. (2007). Plasma chromogranin A is a useful marker of disease progression in patients with midgut neuroendocrine tumours. Clinical Endocrinology, 66(2), 220–227. https://doi.org/10.1111/j.1365-2265.2006.02715.x

FAQ’s:

• What is Chromogranin A?
  An acidic glycoprotein widely expressed by neuroendocrine cells and located in secretory vesicles.

• Which gene encodes CgA?
  In humans, the chromogranin A protein is encoded by the CHGA gene.

• What are test indications?
  Diagnosing neuroendocrine tumours, evaluating symptoms, estimating prognosis, and monitoring treatment response.

• How should blood be collected?
  Collect 3.0 ml in a red-capped plain tube; never use a gel tube.

• What is normal range?
  The normal reference range for Chromogranin A is less than 39 ng/L.

• Which cancers elevate CgA?
  Pancreatic cancer, prostate cancer, pheochromocytoma, carcinoid tumors, and medullary thyroid carcinoma.

• Can non-cancerous conditions raise CgA?
  Yes, renal failure, liver failure, pregnancy, hypertension, and proton pump inhibitors cause elevation.

• What detection methods are used?
  Enzyme-linked immunosorbent assay (ELISA) is used clinically, while radio-immuno assay (RIA) is for research.

• What are test limitations?
  Low proliferative index or poorly differentiated tumors may give false-negative results.

  Related Tests

• Synaptophysin 
• 5-HIAA (5-Hydroxyindoleacetic Acid) Urine Test
• Neuron-Specific Enolase (NSE) Blood Test